EA200300580A1 - Соединения лактама - Google Patents

Соединения лактама

Info

Publication number
EA200300580A1
EA200300580A1 EA200300580A EA200300580A EA200300580A1 EA 200300580 A1 EA200300580 A1 EA 200300580A1 EA 200300580 A EA200300580 A EA 200300580A EA 200300580 A EA200300580 A EA 200300580A EA 200300580 A1 EA200300580 A1 EA 200300580A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lactam
connections
alaninyl
methylbutyryl
benzazepin
Prior art date
Application number
EA200300580A
Other languages
English (en)
Other versions
EA005954B1 (ru
Inventor
Джеймс Эдмунд Одиа
Варгес Джон
Ли Х. Лэйтимер
Стэйси Лей МакДэниэл
Джеффри Скотт Ниссен
Юджин Д. Торсетт
Джей С. Танг
Original Assignee
Эли Лилли Энд Компани
Элан Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани, Элан Фармасьютикалз, Инк. filed Critical Эли Лилли Энд Компани
Publication of EA200300580A1 publication Critical patent/EA200300580A1/ru
Publication of EA005954B1 publication Critical patent/EA005954B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Данное изобретение относится к соединению (N)-((S)-2-гидрокси-3-метилбутирил)-1-(L-аланинил)-(S)-1-амино-3-метил-4,5,6,7-тетрагидро-2H-3-бензазепин-2-ону, содержащим его композициям и способам их применения.Отчет о международном поиске был опубликован 2003.03.06
EA200300580A 2000-11-17 2001-11-05 Соединения лактама EA005954B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17
PCT/US2001/027799 WO2002047671A2 (en) 2000-11-17 2001-11-05 Lactam compound to inhibit beta-amyloid peptide release or synthesis

Publications (2)

Publication Number Publication Date
EA200300580A1 true EA200300580A1 (ru) 2003-10-30
EA005954B1 EA005954B1 (ru) 2005-08-25

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300580A EA005954B1 (ru) 2000-11-17 2001-11-05 Соединения лактама

Country Status (34)

Country Link
US (1) US20050261495A1 (ru)
EP (1) EP1341531B1 (ru)
JP (1) JP4116437B2 (ru)
KR (1) KR100819679B1 (ru)
CN (1) CN1486184A (ru)
AR (1) AR035927A1 (ru)
AU (2) AU4319202A (ru)
BR (1) BR0115427A (ru)
CA (1) CA2427227C (ru)
CY (1) CY1106366T1 (ru)
CZ (1) CZ20031351A3 (ru)
DE (1) DE60126132T2 (ru)
DK (1) DK1341531T3 (ru)
DZ (1) DZ3453A1 (ru)
EA (1) EA005954B1 (ru)
EC (1) ECSP034600A (ru)
ES (1) ES2278804T3 (ru)
HK (1) HK1059731A1 (ru)
HR (1) HRP20030383B1 (ru)
HU (1) HU228117B1 (ru)
IL (2) IL155960A0 (ru)
MX (1) MXPA03004292A (ru)
MY (1) MY134559A (ru)
NO (1) NO324324B1 (ru)
NZ (1) NZ525854A (ru)
PE (1) PE20020802A1 (ru)
PL (1) PL212199B1 (ru)
PT (1) PT1341531E (ru)
SI (1) SI1341531T1 (ru)
SK (1) SK288065B6 (ru)
TW (1) TWI305204B (ru)
UA (1) UA74849C2 (ru)
WO (1) WO2002047671A2 (ru)
ZA (1) ZA200303789B (ru)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
JP5039543B2 (ja) 2005-04-08 2012-10-03 第一三共株式会社 ピリジルメチルスルホン誘導体
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
WO2007088878A1 (ja) * 2006-01-31 2007-08-09 Api Corporation ベンゾアゼピノン類の製造方法
EP2121633A2 (en) 2007-02-12 2009-11-25 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2193117A1 (en) * 2007-07-16 2010-06-09 Wyeth a Corporation of the State of Delaware Inhibitors of beta amyloid production
EA017286B1 (ru) 2007-08-14 2012-11-30 Эли Лилли Энд Компани Ингибиторы гамма-секретазы
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
EP2489656A1 (en) 2007-12-21 2012-08-22 Ligand Pharmaceuticals Inc. Selective androgen receptor modulators (sarms) and uses thereof
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
BR112012008849A2 (pt) 2009-10-14 2015-09-22 Schering Corp composto, composição farmacêutica, e, uso de um composto
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
SI2606134T1 (sl) 2010-08-17 2019-08-30 Sirna Therapeutics, Inc. RNA-INTERFERENČNO POSREDOVANO ZAVIRANJE IZRAŽANJA GENA VIRUSA HEPATITISA B (HBV) Z UPORABO KRATKE INTERFERENČNE NUKLEINSKE KISLINE (siNA)
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2615916B1 (en) 2010-09-16 2017-01-04 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel erk inhibitors
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP3919620A1 (en) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
JP2015527398A (ja) 2012-09-07 2015-09-17 マサチューセッツ アイ アンド イヤー インファーマリー 聴覚喪失治療
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
PL2925888T3 (pl) 2012-11-28 2018-03-30 Merck Sharp & Dohme Corp. Kompozycje i sposoby do stosowania w leczeniu nowotworów
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
AU2017268078B2 (en) 2016-05-16 2023-03-02 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10947234B2 (en) 2017-11-08 2021-03-16 Merck Sharp & Dohme Corp. PRMT5 inhibitors
EP3743057A4 (en) 2018-01-26 2021-11-17 Massachusetts Eye & Ear Infirmary TREATMENT OF HEARING LOSS
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
BR112022012032A2 (pt) 2019-12-17 2022-09-06 Merck Sharp & Dohme Llc Inibidores de prmt5
US20240116945A1 (en) 2022-09-02 2024-04-11 Merck Sharp & Dohme Llc Exatecan-derived topoisomerase-1 inhibitors pharmaceutical compositions, and uses thereof
WO2024091437A1 (en) 2022-10-25 2024-05-02 Merck Sharp & Dohme Llc Exatecan-derived adc linker-payloads, pharmaceutical compositions, and uses thereof
WO2024129628A1 (en) 2022-12-14 2024-06-20 Merck Sharp & Dohme Llc Auristatin linker-payloads, pharmaceutical compositions, and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL196641B1 (pl) * 1996-12-23 2008-01-31 Elan Pharm Inc Związki laktamowe i środek farmaceutyczny
AU4707999A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU1569501A (en) * 1999-11-09 2001-06-06 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
JP2005538031A (ja) * 2000-11-17 2005-12-15 イーライ・リリー・アンド・カンパニー ラクタム化合物

Also Published As

Publication number Publication date
DE60126132D1 (de) 2007-03-08
DZ3453A1 (fr) 2002-06-20
ECSP034600A (es) 2003-06-25
EP1341531A2 (en) 2003-09-10
KR20030051846A (ko) 2003-06-25
ES2278804T3 (es) 2007-08-16
DK1341531T3 (da) 2007-05-14
SI1341531T1 (sl) 2007-06-30
CY1106366T1 (el) 2011-10-12
BR0115427A (pt) 2003-10-07
MXPA03004292A (es) 2004-02-12
NO20032236L (no) 2003-07-10
NO324324B1 (no) 2007-09-24
HUP0301842A2 (hu) 2003-09-29
US20050261495A1 (en) 2005-11-24
CA2427227C (en) 2010-08-17
MY134559A (en) 2007-12-31
AU2002243192B2 (en) 2006-07-20
WO2002047671A3 (en) 2003-03-06
HK1059731A1 (en) 2004-07-16
CZ20031351A3 (cs) 2003-11-12
EA005954B1 (ru) 2005-08-25
WO2002047671A2 (en) 2002-06-20
SK5592003A3 (en) 2003-12-02
HRP20030383B1 (en) 2007-12-31
UA74849C2 (en) 2006-02-15
TWI305204B (en) 2009-01-11
SK288065B6 (sk) 2013-04-03
IL155960A0 (en) 2003-12-23
ZA200303789B (en) 2004-08-16
KR100819679B1 (ko) 2008-04-04
HRP20030383A2 (en) 2005-10-31
DE60126132T2 (de) 2007-10-18
AR035927A1 (es) 2004-07-28
PT1341531E (pt) 2007-04-30
PE20020802A1 (es) 2002-09-10
NZ525854A (en) 2004-06-25
EP1341531B1 (en) 2007-01-17
CA2427227A1 (en) 2002-06-20
JP4116437B2 (ja) 2008-07-09
HUP0301842A3 (en) 2010-03-29
PL212199B1 (pl) 2012-08-31
PL362688A1 (en) 2004-11-02
NO20032236D0 (no) 2003-05-16
IL155960A (en) 2009-06-15
HU228117B1 (en) 2012-11-28
CN1486184A (zh) 2004-03-31
AU4319202A (en) 2002-06-24
JP2004517090A (ja) 2004-06-10

Similar Documents

Publication Publication Date Title
EA200300580A1 (ru) Соединения лактама
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
EA200200940A1 (ru) Производные азетидина, способ их получения и содержащие их фармацевтические композиции
CY1106682T1 (el) Ενωση λακταμης
EA200200530A1 (ru) Гетероциклические замещенные пиразолоны
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
EA199900373A2 (ru) Фармацевтические композиции
EA200301073A1 (ru) N-(2-арилэтил)бензиламины в качестве антагонистов 5-ht-рецептора
BR9804214A (pt) Compostos.
EA200100588A1 (ru) Пиперидины как модуляторы ccr5
EA200100411A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200100412A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
EA200200479A1 (ru) Новые олигосахариды, их получение и содержащие их фармацевтические композиции
EA200400815A1 (ru) Контролируемый синтез зипразидона и его композиции
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
DK1404377T3 (da) Forbedrede chelatorkonjugater
EA200501250A1 (ru) Композиция, содержащая смесь активных начал, и способ ее получения
EA200400259A1 (ru) Дезинфицирующий раствор на основе гипохлорита натрия и способ его получения
EA200201138A1 (ru) Пептид, модулирующий рецептор тромбопоэтина
EA200500899A1 (ru) Антагонисты аденозиндифосфатного рецептора тромбоцитов
EA200000086A1 (ru) Алатрофлоксациновые парентеральные составы
TR200002932T2 (tr) Azabisayklik 5HT1 Alıcı liganolları
BR9902084A (pt) Heterociclos.
ES2195306T3 (es) Composiciones de blanqueo.
EA199900235A1 (ru) Аморфные бензотиофены, способы получения и способы применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU